Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 20


A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes.

Tse WF, Yang W, Huang W.

Clinicoecon Outcomes Res. 2015 Aug 11;7:431-9. doi: 10.2147/CEOR.S85535. eCollection 2015. Review.


The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.

Estill J, Salazar-Vizcaya L, Blaser N, Egger M, Keiser O.

PLoS One. 2015 Mar 20;10(3):e0119299. doi: 10.1371/journal.pone.0119299. eCollection 2015.


Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.

Nichols BE, Sigaloff KC, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, Jordan MR, Hallett TB, Boucher CA, de Wit TF, van de Vijver DA.

J Int AIDS Soc. 2014 Dec 5;17:19164. doi: 10.7448/IAS.17.1.19164. eCollection 2014.


HIV epidemic control-a model for optimal allocation of prevention and treatment resources.

Alistar SS, Long EF, Brandeau ML, Beck EJ.

Health Care Manag Sci. 2014 Jun;17(2):162-81. doi: 10.1007/s10729-013-9240-4. Epub 2013 Jun 23.


Parenting styles and emotional intelligence of HIV-affected children in Thailand.

Lee SJ, Li L, Thammawijaya P.

AIDS Care. 2013;25(12):1536-43. doi: 10.1080/09540121.2013.793264. Epub 2013 May 7.


Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.

Estill J, Egger M, Blaser N, Vizcaya LS, Garone D, Wood R, Campbell J, Hallett TB, Keiser O; IeDEA Southern Africa.

AIDS. 2013 Jun 1;27(9):1483-92. doi: 10.1097/QAD.0b013e328360a4e5.


A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa.

Leisegang R, Maartens G, Hislop M, Sargent J, Darkoh E, Cleary S.

PLoS One. 2013;8(2):e53570. doi: 10.1371/journal.pone.0053570. Epub 2013 Feb 6.


Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.

Sempa J, Ssennono M, Kuznik A, Lamorde M, Sowinski S, Semeere A, Hermans S, Castelnuovo B, Manabe YC.

BMC Public Health. 2012 Sep 4;12:736. doi: 10.1186/1471-2458-12-736.


HIV treatment as prevention: issues in economic evaluation.

Bärnighausen T, Salomon JA, Sangrujee N.

PLoS Med. 2012;9(7):e1001263. doi: 10.1371/journal.pmed.1001263. Epub 2012 Jul 10. Review.


HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.

Meyer-Rath G, Over M.

PLoS Med. 2012;9(7):e1001247. doi: 10.1371/journal.pmed.1001247. Epub 2012 Jul 10.


Current practices in laboratory monitoring of HIV infection.

Vajpayee M, Mohan T.

Indian J Med Res. 2011 Dec;134(6):801-22. doi: 10.4103/0971-5916.92627. Review.


Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings.

Leisegang R, Maartens G, Hislop M, Regensberg L, Cleary S.

BMC Health Serv Res. 2010 Jul 2;10 Suppl 1:S3. doi: 10.1186/1472-6963-10-S1-S3.


Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.

Walensky RP, Ciaranello AL, Park JE, Freedberg KA.

Clin Infect Dis. 2010 Jul 1;51(1):85-92. doi: 10.1086/653119. Review.


Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.

Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, Messou E, Cotich KL, Walensky RP, Freedberg KA; CEPAC-International Investigators.

J Acquir Immune Defic Syndr. 2010 Jul;54(3):258-68. doi: 10.1097/QAI.0b013e3181d0db97.


Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy.

Johansson KA, Robberstad B, Norheim OF.

AIDS Res Ther. 2010 Jan 16;7(1):3. doi: 10.1186/1742-6405-7-3.


Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges.

Wester CW, Bussmann H, Koethe J, Moffat C, Vermund S, Essex M, Marlink RG.

HIV Ther. 2009 Sep 1;3(5):501-526.


Can we spend our way out of the AIDS epidemic? A world halting AIDS model.

Smith RJ, Li J, Gordon R, Heffernan JM.

BMC Public Health. 2009 Nov 18;9 Suppl 1:S15. doi: 10.1186/1471-2458-9-S1-S15.


Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.

May S, Gamst A, Haubrich R, Benson C, Smith DM.

J Acquir Immune Defic Syndr. 2010 Feb;53(2):194-201. doi: 10.1097/QAI.0b013e3181ba37a7.


Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay.

Sivapalasingam S, Wangechi B, Marshed F, Laverty M, Essajee S, Holzman RS, Valentine F.

PLoS One. 2009 Aug 28;4(8):e6828. doi: 10.1371/journal.pone.0006828.


Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.

Korenromp EL, Williams BG, Schmid GP, Dye C.

PLoS One. 2009 Jun 17;4(6):e5950. doi: 10.1371/journal.pone.0005950.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk